%0 Journal Article
%T 曲妥珠单抗治疗1 8 5例HER2阳性乳腺癌患者的心脏安全性评价
%A 佟仲生
%A 孟文静
%A 张继博
%A 李淑芬
%J 肿瘤防治研究
%D 2018
%R 10.3971/j.issn.1000-8578.2018.17.0975
%X 摘要 目的 探讨HER2阳性乳腺癌患者应用曲妥珠单抗治疗的心脏安全性。方法 185例HER2阳性乳腺癌患者接受每3周一次的曲妥珠单抗治疗，首次以负荷剂量8 mg/kg给药，此后每3周给予6 mg/kg静脉滴注，接受治疗4~36周期，观察其心脏安全性。结果 接受曲妥珠单抗治疗的HER2阳性乳腺癌患者中位治疗周期数为17个（4~36个），88例（47.6%）出现LVEF下降、74例（40.0%）出现瓣膜反流（新增+加重）、16例（8.0%）出现左室舒张功能下降。发生心脏毒性88例（47.6%），其中Ⅰ级心脏毒性83例、Ⅱ级心脏毒性5例，未见Ⅲ级心脏毒性发生。结论 曲妥珠单抗对HER2阳性乳腺癌患者心脏功能有一定影响，总体安全性良好。但是，在治疗中仍需注意评估与监测
%K A Predictor of Risk and Prognosis of Breast Cancer
%K Tanshinone ⅡA Enhances Chemosensitivity of Breast Cancer Cells to Doxorubicin and Related Mechanism
%K In Situ Hybridization Status of 568 Cases of HER2 Equivocal Breast Cancer
%K Safety and Efficacy of Percutaneous Vertebroplasty on Spinal Metastases with Incomplete Posterior Wall
%K Progress of Molecular Imaging in Diagnosis of HER2 Positive Tumors
%K Apatinib Suppresses Proliferation and Induced Apoptosis of Human Breast Cancer Cell Line MDA-MB-231 Through Glycolytic Inhibition
%K Progress of Whole Exon Sequencing in Pathogenesis and Diagnosis of Breast Cancer
%K Feedback Activation of STAT3 Confers Resistance of HER2-positive Breast Cancer Cells to Lapatinib
%K Influence of NRP-1 Monoclonal Antibody on Growth of Breast Cancer Xenografts in Nude Mouse
%U http://www.zlfzyj.com/CN/abstract/abstract9108.shtml